Novel tests give great opportunities for earlier and more precise diagnostics. At the same time, new tests expand disease, produce patients, and cause unnecessary harm in overdiagnosis and overtreatment. How can we evaluate diagnostics to obtain the benefits and avoid harm? One way is to pay close attention to the diagnostic process and its core concepts. Doing so reveals 3 errors that expand disease and increase overdiagnosis. The first error is to decouple diagnostics from harm, eg, by diagnosing insignificant conditions. The second error is to bypass proper validation of the relationship between test indicator and disease, eg, by introducing biomarkers for Alzheimer's disease before the tests are properly validated. The third error is to couple the name of disease to insignificant or indecisive indicators, eg, by lending the cancer name to preconditions, such as ductal carcinoma in situ. We need to avoid these errors to promote beneficial testing, bar harmful diagnostics, and evade unwarranted expansion of disease. Accordingly, we must stop identifying and testing for conditions that are only remotely associated with harm. We need more stringent verification of tests, and we must avoid naming indicators and indicative conditions after diseases.
| INTRODUCTION: WHAT IS THE PROBLEM?
Novel tests provide fantastic opportunities for early diagnostics, enabling us to predict and prevent disease or to reduce its harm.
Despite good intentions and promising results, early diagnostics is increasingly criticized for creating overdiagnosis, ie, the detection of (a condition that is classified as) disease without benefit for the person in reduced morbidity or mortality, or increased quality of life. [1] [2] [3] [4] No doubt, finding indicators, precursors, or signs of disease early can be life-saving to patients. However, in cases where persons would not have experienced symptoms, suffering, or reduced quality or length of life, if such entities were not identified, they may in fact be harmed by (subsequent) testing and unnecessary treatment. Additionally, it represents a misuse of resources.
Why has overdiagnosis increased? The first and trivial answer is that awareness has replaced previous neglect. Second, definitions of disease have expanded. 5, 6 By increasing sensitivity or lowering diagnostic thresholds, we are identifying ever milder conditions, and by looking harder, we find more. 7, 8 Third, we also find new indicators (signs, markers, precursors) to identify potential disease, 9 eg, by using prostate-specific antigen (PSA) to identify prostate cancer risk or using multianalyte blood tests to identify a wide range of cancers. 10 Fourth, new or different diagnostic methods are introduced to detect disease. 5 For example, CT angiography has replaced ventilation-perfusion (VQ) scanning, for identifying pulmonary embolism, doubling the number of persons being diagnosed. 11 Fifth, we look for and handle risk factors as diseases. 12, 13 Sixth, there is a strong and not always warranted belief in early detection and a cognitive bias that "early is better." 14 The core of the problem is that we do not know whether what we detect will actually develop into disease. 15 More precisely, it is uncertain whether the indicator that we identify with our tests (also referred to as indicative phenomenon, indicating condition, or predisease), 8 such as faecal occult blood (FOB), polyps, ductal carcinoma in situ (DCIS), or biomarkers, will actually result in symptoms, disease, and death. Body mass index (BMI) "Obesity" Harms related to diseases, such as diabetes, cardiovascular disease, and renal failure. These diseases can ultimately lead to death.
Harm of subsequent testing and treatment is not included.
Summary points
• Uncritical enthusiasm for early detection expands disease and results in overdiagnosis and overtreatment. There are 3 reasons for this:
1. Test indicators are decoupled from harm: Conditions that may not lead to disease are defined as disease and handled as harmful.
2. The relationship between indicator and harm is poorly verified.
3. Indicators are given names after the diseases they indicate and thus appear more alarming than they are.
• To avoid this, we need to take 3 actions:
1. We must stop identifying and testing for conditions that are only remotely associated with harm. In particular, we need to explain to patients that test indicators are indicators and not disease.
2. We must apply stringent verifications of tests.
3. We must avoid naming indicators and indicative conditions after diseases.
Three leaps of faith to avoid:
• From test indicator (eg, polyps) to disease.
• From early (detection) to better health and no harm.
• From being able to do something to doing something good. people's sufferings is challenging. [23] [24] [25] Otherwise, indicators will come to define disease more than being validated by them.
| Altering validation criteria

| Coupling disease name to uncertain phenomena
Decoupling testing from harm and lack of validation is only part of the problem. For sure, both introduce uncertainty. But uncertainty in diagnostics is not new. We have struggled with nonperfect diagnostic tests for ages, eg, in false (negative and positive) test results.
However, when indolent lesions ("ductal intraepithelial neoplasia" or It is important to notice that these 3 errors are not present in every case of overdiagnosis and are not 3 sequential steps in every case of overdiagnosis. They all merit careful considerations on their own right.
| The slippery path from new tests to overdiagnosis
In the decoupling of test and harm, we are subject to 2 leaps of faith.
First, we leap from test results (indicator) to disease. In situ neoplasms or "papillary urothelial neoplasia of low malignant potential" come to designate cancers. While it can be perfectly warranted to pay attention to biomarkers and risks factors for disease, it is not warranted to handle risk factors as disease (per se). 12, 28 The second leap of faith is that we believe that early detection is better than later detection.
14 In this, we presuppose a linear or positive progression, which often is warranted, but not always. 29, 30 Early or small is not always the same as good. 31 Moreover, actionability overshadows uncertainty. When we are able to act or intervene, the indicators increase in importance. As we are able to remove polyps or DCIS, they become significant. No doubt, if we remove necessary conditions or risk factors for a disease, we may remove the disease. But at the same time, we may come to confuse necessary conditions with the disease or with its causes.
Although blood is a necessary condition for sepsis, we do not remove people's blood to avoid sepsis. Accordingly, not all indicators are important, and some indicators, while important, are not helpful in reducing harm.
| WHAT IS THE SOLUTION?
In the identified errors and leaps of faith lie the solutions. First, we must stop identifying and testing for conditions that are only remotely associated with experienced suffering or harm. Second, we need more FIGURE 1 Relationship among experienced suffering/harm, disease, and test; A, how symptoms and signs come to define disease due to validated connections with harm. B, What happens when additional tests are introduced and validated by "gold standard" tests. C, How tests are named by the disease and its expected harm without proper validation, which may ascribe unwarranted predictive power to the test stringent verification of tests, and third, we must avoid naming indicators and indicative conditions after diseases.
| Distinguish between uncertainties
The decoupling between tests and harm conflates 2 types of uncertainty. There exists 1 kind of uncertainty between diagnostic test results (for a given disease) and harm ("verifying 1" in Figure 1B , 
| Change the game of the name
As the test results may be decoupled from harm, the disease name may give them unwarranted importance. As illustrated in Figure 1, there is little or no validation of the relationship between the indicator test result and harm. Nonetheless, naming the indicator after the disease it indicates unwarrantedly couples it to harm. The term "carcinoma" in DCIS indicates that there is a closer connection to (breast) cancer than what may be warranted. 29 It also alters conceptions and management of these conditions. 27 Hence, giving indicators disease-like names advances the impression that we know more than we actually do and contributes to the expansion of disease and overdiagnosis. The case of DCIS is particularly interesting because it was originally thought to be a variant of breast cancer but (partly due to screening) showed more appropriately to be considered a precursor of the disease. Therefore, we should continue the encouraging improvements in the field, such as calling DCIS "indolent lesions of epithelial origin" (IDLE conditions), 32 using "urothelial neoplasia of low malignant potential" instead of grade 1 papilloma, and "papillary urothelial neoplasia of low malignant potential" instead of papilloma and grade1 carcinoma. 29, 33 Finding indicators and treating indicative conditions may clearly be warranted, but this can be done without calling them diseases. Instead of "colorectal cancer screening program," we should call it "polyp identification and removal program." Thus, although the decoupling of tests and harm has some injurious implications, we can turn the trend and apply our diagnostic innovations to help people, and not to harm them.
| Verify relationship between indicators and experienced suffering or harm
Another way to bar the expansion of disease and overdiagnosis is to design studies to verify the relationship between indicators and harm. is the best we can get. However, they should not be confused with the ultimate measure of disease, which is experienced suffering or harm.
When stopping to tag indicators with names of harm or disease, we would undermine the unwarranted eager to find and eliminate indicators that do not develop suffering or become harmful. That is, we would stop the uncontrolled expansion of disease. We therefore must stop talking about "unharmful disease," 16 "indolent disease," "inconsequential disease," 11 or "low-risk disease." 30 Disease is harmful (in some sense).
Conditions used as indicators may be indolent and become harmful, but they are not harmful per se. Clinicians need to be aware of this, and patients should be informed about it. Researchers must strive to verify the connection between indicators and harm, and health policy makers must avoid making "the war on cancer" to a "war on indicators." 9 No doubt, identifying and targeting indicators (biomarkers, precursors, and risk factors) can be of outmost import for people's health.
However, indicators are not diseases. 12, 28 Both have uncertain connections to harm. While both risk factors and indicators can be principal to avoid or ameliorate harm, we do not whether they will do so-or whether they will result in subsequent unnecessary diagnostics and treatment, anxiety, or harm. This urges us to be cautious.
| CONCLUSION
New tests may come to expand disease, produce patients, and cause unnecessary harm instead of early detection, avoided or reduced morbidity, or mortality reduction. To avoid this, we should stop identifying and testing for conditions that are only remotely associated with suffering or harm, we ought to verify tests more stringently, and we should avoid naming indicators and indicative conditions after diseases. In short, we should bring the naming of disease on par with 
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